X-SCID Gene Therapy Risks Not Generalizable To Other Conditions, Cmte. Says
• By Janet Coleman
FDA's Cellular, Tissue & Gene Therapies Advisory Committee points to unique factors in the biological basis of X-linked severe combined immunodeficiency disorder and the fact that leukemia cases have been seen in only one study.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
